NCT05722327View on ClinicalTrials.gov

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Colon CancerColorectal Cancer

Interventions

DRUG

MRTX849

Given by PO (mouth)

DRUG

Irinotecan

Given by IV (vein)

DRUG

Cetuximab

Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Mirati Therapeutics

All Listed Sponsors

collaborator

Mirati Therapeutics

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER